Use of Protein Microarrays To Define the Humoral Immune Response in Leprosy Patients and Identification of Disease-State-Specific Antigenic Profiles

ABSTRACT Although the global prevalence of leprosy has decreased over the last few decades due to an effective multidrug regimen, large numbers of new cases are still being reported, raising questions as to the ability to identify patients likely to spread disease and the effects of chemotherapy on the overall incidence of leprosy. This can partially be attributed to the lack of diagnostic markers for different clinical states of the disease and the consequent implementation of differential, optimal drug therapeutic strategies. Accordingly, comparative bioinformatics and Mycobacterium leprae protein microarrays were applied to investigate whether leprosy patients with different clinical forms of the disease can be categorized based on differential humoral immune response patterns. Evaluation of sera from 20 clinically diagnosed leprosy patients using native protein and recombinant protein microarrays revealed unique disease-specific, humoral reactivity patterns. Statistical analysis of the serological patterns yielded distinct groups that correlated with phenolic glycolipid I reactivity and clinical diagnosis, thus demonstrating that leprosy patients, including those diagnosed with the paucibacillary, tuberculoid form of disease, can be classified based on humoral reactivity to a subset of M. leprae protein antigens produced in recombinant form.

[1]  D. Smith,et al.  Purification, characterization, gene sequence, and significance of a bacterioferritin from Mycobacterium leprae , 1994, The Journal of experimental medicine.

[2]  M. Huerre,et al.  Specific anti-M leprae PGL-I antibodies and Mitsuda reaction in the management of household contacts in New Caledonia. , 1989, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[3]  P. Brennan,et al.  The major native proteins of the leprosy bacillus. , 1990, The Journal of biological chemistry.

[4]  Pierre Baldi,et al.  Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Cole,et al.  Comparative Analysis of B- and T-Cell Epitopes of Mycobacterium leprae and Mycobacterium tuberculosis Culture Filtrate Protein 10 , 2004, Infection and Immunity.

[6]  P. Brennan,et al.  Isolation and characterization of the highly immunogenic cell wall-associated protein of Mycobacterium leprae. , 1989, Journal of immunology.

[7]  S. Cole,et al.  Characterization of a 34-Kilodalton Protein ofMycobacterium leprae That Is Isologous to the Immunodominant 34-Kilodalton Antigen of Mycobacterium paratuberculosis , 1998, Infection and Immunity.

[8]  D. Alland,et al.  A major T cell antigen of Mycobacterium leprae is a 10-kD heat-shock cognate protein , 1992, The Journal of experimental medicine.

[9]  J. Morrissey,et al.  Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. , 1981, Analytical biochemistry.

[10]  R. Rees,et al.  Effect of purification steps on the immunogenicity of Mycobacterium leprae. , 1980, British journal of experimental pathology.

[11]  P. Andersen,et al.  TB vaccine strategies--what is needed to solve a complex problem? , 2006, Tuberculosis.

[12]  P. Brennan,et al.  Infection by Mycobacterium leprae of household contacts of lepromatous leprosy patients from a post-elimination leprosy region of Colombia. , 2005, Memórias do Instituto Oswaldo Cruz.

[13]  P. Klatser,et al.  Prospective Study of Serological Conversion as a Risk Factor for Development of Leprosy among Household Contacts , 2004, Clinical Diagnostic Laboratory Immunology.

[14]  J R Yates,et al.  Utilization of genomic sequence information to develop malaria vaccines , 2003, Journal of Experimental Biology.

[15]  Rebecca Harris,et al.  Supervised Self-Organizing Maps in Drug Discovery. 2. Improvements in Descriptor Selection and Model Validation , 2006, J. Chem. Inf. Model..

[16]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[17]  J. Ehrenberg,et al.  Analysis of the Antigenic Profile of Mycobacterium leprae: Cross‐Reactive and Unique Speeificities of Human and Rabbit Antibodies , 1987, Scandinavian journal of immunology.

[18]  I. Longden,et al.  EMBOSS: the European Molecular Biology Open Software Suite. , 2000, Trends in genetics : TIG.

[19]  J. Richardus,et al.  Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. , 2004, Leprosy review.

[20]  W. Liang,et al.  9) TM4 Microarray Software Suite , 2006 .

[21]  G. Ireton,et al.  ML0405 and ML2331 Are Antigens of Mycobacterium leprae with Potential for Diagnosis of Leprosy , 2006, Clinical and Vaccine Immunology.

[22]  S. V. van Beers,et al.  The epidemiology of Mycobacterium leprae: recent insight. , 1996, FEMS microbiology letters.

[23]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. , 1992, Biotechnology.

[24]  Results of a World Health Organization-sponsored workshop on monoclonal antibodies to Mycobacterium leprae , 1985, Infection and immunity.

[25]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[26]  Kim Rutherford,et al.  Artemis: sequence visualization and annotation , 2000, Bioinform..

[27]  S. Cole,et al.  Towards an immunodiagnostic test for leprosy. , 2006, Microbes and infection.

[28]  T. Ottenhoff,et al.  Postgenomic Approach To Identify Novel Mycobacterium leprae Antigens with Potential To Improve Immunodiagnosis of Infection , 2005, Infection and Immunity.

[29]  D. Ridley,et al.  Classification of leprosy according to immunity. A five-group system. , 1966, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[30]  C. Frasch,et al.  A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. , 1982, Analytical biochemistry.

[31]  M S Waterman,et al.  Identification of common molecular subsequences. , 1981, Journal of molecular biology.

[32]  L. Oskam,et al.  Serology: recent developments, strengths, limitations and prospects: a state of the art overview. , 2003, Leprosy review.

[33]  B. Barrell,et al.  Massive gene decay in the leprosy bacillus , 2001, Nature.

[34]  Ersin Bayram,et al.  Supervised Self-Organizing Maps in Drug Discovery. 1. Robust Behavior with Overdetermined Data Sets , 2005, J. Chem. Inf. Model..

[35]  P. Green,et al.  Base-calling of automated sequencer traces using phred. I. Accuracy assessment. , 1998, Genome research.

[36]  P. Brennan,et al.  Structure and antigenicity of the major specific glycolipid antigen of Mycobacterium leprae. , 1982, The Journal of biological chemistry.

[37]  D. Lipman,et al.  Improved tools for biological sequence comparison. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Sampaio,et al.  Role of PGL-I antibody detection in the diagnosis of pure neural leprosy. , 2005, Leprosy review.

[39]  Continued proteomic analysis of Mycobacterium leprae subcellular fractions , 2004, Proteomics.

[40]  Ridley Ds,et al.  Classification of leprosy according to immunity. A five-group system. , 1966 .

[41]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Cole,et al.  Antigen Discovery: a Postgenomic Approach to Leprosy Diagnosis , 2006, Infection and Immunity.